Navigation Links
IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
Date:8/27/2007

d by the FDA and EMEA in a satisfactory manner, the time needed to respond to any issues raised by the FDA and EMEA with regard to regulatory submissions for L-MTP-PE, although the FDA is not bound by the decision of any advisory panel, the possible negative impact that the opinion of the FDA's Oncologic Drugs Advisory Committee that the results of the Company's Phase 3 trial do not provide substantial evidence of effectiveness of L-MTP-PE in the treatment of patients with non-metastatic, resectable osteosarcoma receiving combination chemotherapy would have upon the determination by the FDA whether to approve the marketing application for L- MTP-PE, which would have a material and adverse affect on IDM's business, the possibility that regulatory authorities may not consider preclinical and early clinical development work conducted by Ciba-Geigy and efficacy data from the Phase 3 trial conducted by Children's Oncology Group as adequate for their assessment of L-MTP-PE, which may cause delays in review, may result in the regulatory authorities requiring the Company to conduct additional clinical trials, or may result in a determination by the regulatory authorities that the data does not support marketing approval, whether regulatory authorities will approve L-MTP-PE within the time frame expected by the Company or at all, and whether the Company will be able to manufacture and commercialize L-MTP-PE even if it is approved by regulatory authorities. Other risks affecting the Company and its drug development programs include whether the Company or any of its collaborators will be able to develop pharmaceutical products using the technologies of the Company, whether clinical trial results to date are predictive of results of any future clinical trials, risks associated with completing clinical trials of product candidates, risks involved in the regulatory approval process for the Company's product candidates, the possibility that clinical testing may reveal undesirable
'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... 2015   Inocucor Technologies Inc ., the ... for farmers, has received a notice of allowance ... its patent application to protect Inocucor consortia and ... enhance yields on farms and in greenhouses. ... IN-M1 microbial consortium and its fermentation byproducts, which ...
(Date:7/27/2015)... ... July 27, 2015 , ... BlueInGreen® ... Monday. The venture will bring the world’s most efficient gas dissolution technology to ... and technologies to both the industrial and municipal markets. With offices located in ...
(Date:7/27/2015)... July 27, 2015 The Brain ... winners of its annual Klerman and Freedman Prizes, ... who have been supported by NARSAD Young Investigator ... pursue innovative ideas in neurobiological and psychosocial research, ... for the early detection, treatment, prevention and cure ...
(Date:7/27/2015)... -- IDEXX Laboratories, Inc. (NASDAQ: IDXX ) announced ... 100,000 specimens to IDEXX Reference Laboratories for symmetric dimethylarginine, ... since the breakthrough kidney function test launched in the ... of suffering and death in cats and dogs. The ... accepted kidney disease prevalence data showing that 1 in ...
Breaking Biology Technology:Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3BlueInGreen Brings Water Treatment Technology to Florida 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5
... 6, 2012 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... Officer of Neurocrine Biosciences, will be presenting at the 14th ... The live presentation takes place on Monday, February ... Time.  The presentation will be webcast and may be accessed ...
... 6, 2012  BioStorage Technologies, a global provider of ... chain logistics for the bioscience industry, will host ... in Clinical Trials on Tuesday, March 6, 2012 ... The 2-hour workshop will focus ...
... 2012 UV Flu Technologies, Inc. ( OTCBB: ... ahead of schedule in its continuing program to eliminate all debt. ... the remaining and final convertible note, in the amount of $32,500 ... we have made in the last twelve months is nothing short ...
Cached Biology Technology:BioStorage Technologies to Host Global Sample Management Workshop at Partnerships in Clinical Trials 2UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt 2UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt 3
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... TORONTO, ON Psychologists at the University of ... interaction has the ability to influence an individual,s sensitivity ... clinical implications for doctor-patient relationships and the general well-being ... of studies over the past several decades have demonstrated ...
... CHICAGO --- Northwestern Medicine researchers at the Robert H. ... a new, nontoxic drug made from a chemical in soy ... to the rest of the body. These findings will ... Research Frontiers in Cancer Prevention Research Conference. Genistein, a ...
... at the University of California, San Diego School of ... of federally approved drugs to more than 1,000 proteins ... opening new avenues to repurpose these drugs to treat ... PLoS Computational Biology . "Tuberculosis is currently ...
Cached Biology News:Psychologists identify influence of social interaction on sensitivity to physical pain 2Soy may stop prostate cancer spread 2TB-drugome provides new targets for anti-tuberculosis drug discovery 2
... The dual-bay DNA Engine Dyad ... for DNA amplification (PCR). The chassis ... units (sample-holder, heat-pump assemblies), which hold ... Color display offers graphical programming with ...
... Red fluorescent RNA stain is used to ... or glyoxal) agarose gels and does not ... a 302 nm transilluminator, the stain emits ... on Polaroid film or with a CCD ...
... The MitoPT kit is used in conjunction ... in culture and induce apoptosis according to your ... cells as a negative control). Once you have ... MitoPT solution to each population and incubate the ...
... Disruption of the mitochondrial transmembrane ... intracellular events that occur following induction ... Detection Kit utilizes a lipophilic cation, ... activity marker. MitoLight is a mitochondrial ...
Biology Products: